ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early
For lymphoma that came back within a year, going straight to CAR-T beat the decades-old chemotherapy-then-transplant approach, and later improved survival.
ZUMA-7 randomised 359 patients with large B-cell lymphoma that was refractory to, or relapsed within 12 months of, first-line chemo-immunotherapy to axicabtagene ciloleucel (axi-cel) or standard second-line salvage chemotherapy followed by high-dose therapy and autologous transplant in responders. The primary endpoint was event-free survival. Median EFS was 8.3 versus 2.0 months (hazard ratio 0.40) and 24-month EFS 41% versus 16%; complete response was 65% versus 32%. Only about a third of standard-arm patients reached transplant, and 56% went on to receive CAR-T off protocol. Despite that crossover, the later analysis (Westin et al., NEJM 2023) showed improved overall survival with axi-cel (4-year OS 54.6% versus 46.0%; hazard ratio 0.73).
- 359 patients with primary refractory or early-relapsing (within 12 months) LBCL; axi-cel vs salvage chemotherapy plus autologous transplant.
- Median EFS 8.3 vs 2.0 months; hazard ratio 0.40; 24-month EFS 41% vs 16%.
- Overall response 83% vs 50%; complete response 65% vs 32%.
- Only 36% of standard-arm patients proceeded to transplant; 56% later received cellular therapy off protocol.
- Overall survival improved (4-year OS 54.6% vs 46.0%; HR 0.73), the first survival gain in this setting in decades.
- Grade 3 or higher CRS 6%; grade 3 or higher neurological events 21%; no bridging chemotherapy allowed (steroids only).
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
- Applies only to early relapse or primary refractory disease; late relapse was excluded.
- No bridging chemotherapy was permitted, so patients with rapidly progressive disease may not have been enrolled.
- The parallel BELINDA trial of tisagenlecleucel in the same setting was negative, showing the result depends on product and logistics.
- Costs and centre capacity limit uptake outside high-income countries.
TRANSFORM confirmed ZUMA-7's conclusion with a different CD19 CAR-T and a more permissive design that allowed bridging chemotherapy, making the results closer to real-world practice. Liso-cel's low toxicity makes it attractive for older or frailer patients and for outpatient delivery. Together the two trials made CAR-T the standard second-line therapy for early-relapsing aggressive lymphoma.
ZUMA-1 showed that CAR-T can cure a meaningful fraction of adults whose aggressive lymphoma no longer responds to chemotherapy, a group with a historical median survival of about six months (SCHOLAR-1). Axi-cel became the first CAR-T approved for lymphoma and later the first to beat standard second-line therapy in ZUMA-7. The comparatively high neurotoxicity of CD28-costimulated products was also first characterised here.